CN109154603A - 用于治疗真菌感染的给药方案 - Google Patents

用于治疗真菌感染的给药方案 Download PDF

Info

Publication number
CN109154603A
CN109154603A CN201780030072.2A CN201780030072A CN109154603A CN 109154603 A CN109154603 A CN 109154603A CN 201780030072 A CN201780030072 A CN 201780030072A CN 109154603 A CN109154603 A CN 109154603A
Authority
CN
China
Prior art keywords
dose
administered
salt
day
neutral form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780030072.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.巴蒂扎尔
P.达鲁瓦拉
J.B.洛克
V.翁
T.桑迪森
D.赛伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seachaid Pharmaceuticals LLC
Original Assignee
Seachaid Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seachaid Pharmaceuticals LLC filed Critical Seachaid Pharmaceuticals LLC
Publication of CN109154603A publication Critical patent/CN109154603A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780030072.2A 2016-03-16 2017-03-15 用于治疗真菌感染的给药方案 Pending CN109154603A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US62/309211 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US62/350591 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US62/415928 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US62/418727 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US62/419076 2016-11-08
US201662436716P 2016-12-20 2016-12-20
US62/436716 2016-12-20
PCT/US2017/022551 WO2017161016A1 (en) 2016-03-16 2017-03-15 Dosing regimens for treatment of fungal infections

Publications (1)

Publication Number Publication Date
CN109154603A true CN109154603A (zh) 2019-01-04

Family

ID=59850952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780030072.2A Pending CN109154603A (zh) 2016-03-16 2017-03-15 用于治疗真菌感染的给药方案

Country Status (8)

Country Link
US (2) US11712459B2 (https=)
EP (2) EP4268896A3 (https=)
JP (3) JP7224916B2 (https=)
CN (1) CN109154603A (https=)
CA (1) CA3017485A1 (https=)
ES (1) ES2955711T3 (https=)
MA (1) MA43825A (https=)
WO (1) WO2017161016A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA43825A (fr) 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
JP7779651B2 (ja) 2017-07-12 2025-12-03 ナップ ファーマシューティカル グループ リミテッド 真菌感染症の処置のための組成物及び方法
EP3806882A4 (en) 2018-06-15 2022-03-23 Cidara Therapeutics, Inc. SYNTHESIS OF AN ANTIFUNGAL WITH ECHINOCANDIN
WO2020086931A1 (en) 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorph of echinocandin antifungal agent
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1339959A (zh) * 1999-03-26 2002-03-13 前技术专业产品公司 抗菌义齿清洁组合物
CN1355699A (zh) * 1999-04-16 2002-06-26 藤泽药品工业株式会社 抗真菌组合物
CN101374502A (zh) * 2006-01-05 2009-02-25 药物技术公司 局部应用的药剂
CN103889221A (zh) * 2011-03-03 2014-06-25 西蔡德制药公司 抗真菌剂及其应用
US20150087583A1 (en) * 2012-03-19 2015-03-26 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
JPH09500103A (ja) 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
WO1996022784A1 (en) 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
PE63998A1 (es) 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
DK1137663T3 (da) 1998-12-09 2007-01-08 Lilly Co Eli Oprensning af Echinocandin-cyclopeptidforbindelser
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HK1040062A1 (zh) 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
HK1040369A1 (zh) 1999-03-03 2002-06-07 Eli Lilly And Company 制备药物口服ecb配方和组合物的方法
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20060276339A1 (en) 2002-10-16 2006-12-07 Windsor J B Methods and compositions for increasing the efficacy of biologically-active ingredients
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
ATE381957T1 (de) 2003-07-22 2008-01-15 Theravance Inc Verwendung eines antimykotischen echinocandin- mittels in kombination mit einem antibakteriellen glycopeptid-mittel
US8753819B2 (en) 2005-07-26 2014-06-17 Rutgers, The State University Of New Jersey Assays for resistance to echinocandin-class drugs
WO2007113386A1 (en) 2006-03-31 2007-10-11 Karyon-Ctt Ltd Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
CN102438590B (zh) 2009-02-25 2013-07-10 施泰福研究澳大利亚有限公司 局部泡沫组合物
WO2010128096A1 (en) 2009-05-07 2010-11-11 Dsm Ip Assets B.V. Method for the preparation of cyclopeptides
DK2470168T3 (en) 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
EP2470190A4 (en) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc ECHINOCANDINDERIVATE
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (en) 2013-01-18 2014-07-24 University Of Utah Research Foundation Modified release osmotic pump for ph-responsive intravaginal drug delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
WO2014145109A1 (en) 2013-03-15 2014-09-18 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Sugar-linker-drug conjugates
AU2014262127B2 (en) 2013-05-01 2019-05-02 Neoculi Pty Ltd Methods for treating bacterial infections
WO2015035102A2 (en) * 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2017049102A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA43825A (fr) 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
CN110290797A (zh) 2016-11-01 2019-09-27 奇达拉治疗公司 用于预防和治疗真菌感染的单剂量方法
WO2018102407A1 (en) 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (en) 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
JP7779651B2 (ja) 2017-07-12 2025-12-03 ナップ ファーマシューティカル グループ リミテッド 真菌感染症の処置のための組成物及び方法
KR20200047550A (ko) 2017-08-03 2020-05-07 시다라 세라퓨틱스, 인코포레이티드 복강내 칸디다증의 예방 방법 및 치료 방법
EP3806882A4 (en) 2018-06-15 2022-03-23 Cidara Therapeutics, Inc. SYNTHESIS OF AN ANTIFUNGAL WITH ECHINOCANDIN

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1339959A (zh) * 1999-03-26 2002-03-13 前技术专业产品公司 抗菌义齿清洁组合物
CN1355699A (zh) * 1999-04-16 2002-06-26 藤泽药品工业株式会社 抗真菌组合物
CN101374502A (zh) * 2006-01-05 2009-02-25 药物技术公司 局部应用的药剂
CN103889221A (zh) * 2011-03-03 2014-06-25 西蔡德制药公司 抗真菌剂及其应用
US20150087583A1 (en) * 2012-03-19 2015-03-26 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
CN104507309A (zh) * 2012-03-19 2015-04-08 奇达拉治疗公司 用于棘白菌素类化合物的给药方案

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OPTIONK. JAMES 等: "Biafungin(CD101), a Novel Echinocandin, Displays a Long Half-life in the Chimpanzee, Suggesting a Once-Weekly IV Dosing Option", 《ABSTR 54TH INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER,ABSTR A-694》 *

Also Published As

Publication number Publication date
US20190216885A1 (en) 2019-07-18
JP7322259B2 (ja) 2023-08-07
JP2023139211A (ja) 2023-10-03
CA3017485A1 (en) 2017-09-21
EP3430400A4 (en) 2019-10-30
JP7224916B2 (ja) 2023-02-20
US20240108684A1 (en) 2024-04-04
JP2022169599A (ja) 2022-11-09
EP3430400A1 (en) 2019-01-23
EP4268896A2 (en) 2023-11-01
US11712459B2 (en) 2023-08-01
ES2955711T3 (es) 2023-12-05
WO2017161016A1 (en) 2017-09-21
EP4268896A3 (en) 2024-01-03
JP2019511496A (ja) 2019-04-25
EP3430400B1 (en) 2023-06-21
MA43825A (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
CN109154603A (zh) 用于治疗真菌感染的给药方案
Perlin Mechanisms of echinocandin antifungal drug resistance
Howard et al. A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Eschenauer et al. Comparison of echinocandin antifungals
Srivastava et al. Emerging virulence, drug resistance and future anti-fungal drugs for Candida pathogens
McCormack et al. Caspofungin: a review of its use in the treatment of fungal infections
Morrison Echinocandin antifungals: review and update
Seyedmousavi et al. Systemic antifungal agents: current status and projected future developments
Chang et al. New developments and directions in the clinical application of the echinocandins
Pound et al. Echinocandin pharmacodynamics: review and clinical implications
Tobudic et al. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases
Giacobbe et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections
Bersani et al. Antifungal drugs for invasive candida infections (ICI) in neonates: Future perspectives
Prażyńska et al. In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation
Spencer et al. Systemic fungal infections: A pharmacist/researcher perspective
Santos et al. Biofilm: A robust and efficient barrier to antifungal chemotherapy
TW201842915A (zh) 組合使用的抗真菌劑
Xu et al. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients
EP3204120B1 (en) Methods and compositions for increasing the potency of antifungal agents
HK40103014A (en) Dosing regimens for treatment of fungal infections
Punia et al. Therapeutic approaches for combating Aspergillus associated infection
Sanchis et al. Efficacy of echinocandins against murine infections by Diutina (Candida) rugosa
Perlin Antifungals
Saghir et al. Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model
HK1261465A1 (en) Dosing regimens for treatment of fungal infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261465

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190104